Ascletis doses the first patient in a global Phase 3 of oral small-molecule GLP-1 ASC30

Ascletis Pharma dosed the first participant in the global Phase 3 program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist, on August 30, 2026 ^[1]. The step moves the drug from paperwork to actual treatment: until then, the public record held only Phase 1/2 data and an FDA clearance to begin Phase 3, with no evidence that any participant had been treated ^[1].

The program runs under two trial registrations, NCT07743463 (AURORA-1) and NCT07743450 (AURORA-2) ^[1]. Together they cover about 4,600 participants at sites in the United States, Europe and Canada ^[1]. AURORA-1 enrolls people with obesity who do not have type 2 diabetes; AURORA-2 enrolls people who do ^[1]. Both test 20 mg, 40 mg and 60 mg maintenance doses over 72 weeks ^[1].

Ascletis has guided to topline results in the third quarter of 2028, an FDA submission by the end of 2028 and a European Medicines Agency submission in early 2029 ^[1].

Where ASC30 sits in a crowded oral race

The company's own framing is unusually modest. Ascletis describes ASC30 as a candidate to become the second oral small-molecule GLP-1 in the United States and Europe, which places it behind orforglipron rather than head-to-head against it ^[1].

That matters because the oral category is already occupied. Lilly's orforglipron, sold as Foundayo, was approved by the FDA in April 2026 and brought in $98 million in its first full quarter ^[1][2]. Novo Nordisk's oral semaglutide — the Wegovy pill — is also on the market, and both are tracked at roughly 15% weight loss ^[1]. A third contender, Structure Therapeutics' aleniglipron, posted about 16.3% placebo-adjusted weight loss at 44 weeks with the 180 mg oral dose in Phase 2 and has guided to a Phase 3 start in the third quarter of 2026, with market entry projected around 2029 ^[1]. As of August 31, 2026, that Structure Phase 3 start had not yet been confirmed ^[1].

One important gap: the sources do not report how much weight ASC30 produced in its earlier Phase 1/2 studies, nor any side-effect or tolerability data. The primary endpoints of AURORA-1 and AURORA-2 are also not described in the sources. Those details are not yet known from the material available here.

Why it matters for patients

For anyone weighing options today, the practical takeaway is about timing, not choice. A first-patient-dosed announcement is the beginning of a large trial, not a product launch. With topline data guided for the third quarter of 2028 and an FDA submission targeted by the end of 2028, ASC30 is — in the words of the coverage — "a 2029 question, not a 2026 one" ^[1].

The longer-term relevance is competitive. Pills are easier to make and ship than injectables, and more approved oral GLP-1 options could eventually change what insurers cover and what people pay. But nothing in these sources says anything about ASC30's expected price, coverage or whether its 72-week results will look better or worse than what is already approved.

The trial itself is also a near-term opportunity of a different kind: roughly 4,600 people across the US, Europe and Canada will receive either ASC30 or a comparator over 72 weeks, and enrollment information for both studies is on the public registry under their NCT numbers ^[1].

What happens next

• Through 2026–2028: AURORA-1 and AURORA-2 enroll and treat participants for 72 weeks across US, European and Canadian sites ^[1].
• Q3 2028: Guided topline results for the Phase 3 program ^[1].
• End of 2028: Targeted FDA submission ^[1].
• Early 2029: Targeted EMA submission ^[1].

Meanwhile the rest of the oral field keeps moving. Structure's aleniglipron Phase 3 start remains an open guided window, and Pfizer/Metsera's berobenatide Phase 3 program — ten trials planned for 2026 — is described as the most significant new competitive entry into the incretin field ^[1]. Whether ASC30 actually lands second among oral small molecules will depend on how those programs run, not on this week's announcement.